

11. The method of claim 1, wherein the overall expression pattern or level of 4, 5, 6, 7, 8, 9, 10, 12, 15, 20, 25, 30, 35, 40, 45, 50, 55 or 60 microRNAs selected from Tables 2, 3, 4, and 5, wherein the microRNAs increase the specificity of the determination, diagnosis or detection of colorectal neoplasia.

12. The method of claim 1, further comprising the step of using the overall expression pattern or level of microRNAs for prognosis, treatment guidance, or monitoring response to treatment of the colorectal neoplasia.

13. A biomarker for colorectal neoplasia disease progression, metastasis or both wherein the biomarker comprises one or more microRNAs and a change in the overall expression of the one or more microRNAs in colorectal neoplasia cells obtained from a patient is indicative of colorectal neoplasia disease progression when compared to the overall expression of the one or more microRNAs expression in normal colorectal neoplasia cells or colorectal neoplasia cells obtained at an earlier timepoint from the same patient, wherein the overexpression of the combination of at miR19a and miR19b, or miR19a and miR19b and miR15b, is indicative of colorectal cancer.

14. The biomarker of claim 13, further comprising the analysis of one or more of the following microRNAs miR29a, miR92a, miR141, miR18a, miR19a, miR19b, miR15b, miR29a or miR335.

15. The biomarker of claim 13, wherein the biomarker further comprises microRNAs that are underexpressed in colorectal neoplasia selected from:

hsa-miR-636;
 hsa-miR-876-3p;
 hsa-miR-1537;
 hsa-miR-630;
 hsa-miR-380*;
 hsa-miR-338-5p;
 hsa-miR-573;
 hsa-miR-182*;
 hsa-miR-518c*;
 hsa-miR-187*;
 hsa-miR-1233;
 hsa-miR-449b;
 hsa-miR-1204;
 hsa-miR-518d-3p;
 hsa-miR-1290;
 hsa-miR-144:9.1;
 hsa-miR-105;
 hsa-miR-298;
 hsa-miR-491-5p;
 hsa-miR-576-3p;
 hsa-miR-590-3p;
 hsa-miR-1257;
 hsa-miR-1225-3p;
 hsa-miR-127-3p;
 hsa-miR-936;
 hsa-miR-379;
 hsa-miR-664*;
 hsa-miR-548j;
 hsa-miR-130b*;
 hsa-miR-515-3p.

16. The biomarker of claim 13, wherein the biomarker further comprises microRNAs that are overexpressed in colorectal neoplasia selected from:

hsa-miR-302b;
 hsa-miR-125a-5p;

-continued

hsa-miR-424;
 hsa-miR-125b;
 hsa-miR-100;
 hsa-miR-768-3p:11.0;
 hsa-miR-24;
 hsa-miR-23a;
 hsa-miR-1274b;
 hsa-miR-27a;
 hsa-miR-26b;
 hsa-miR-30d;
 hsa-miR-520h;
 hsa-miR-520g;
 hsa-miR-302*;
 hsa-miR-518c;
 hsa-miR-335;
 hsa-miR-29a;
 hsa-miR-152;
 hsa-miR-191;
 hsa-miR-17;
 hsa-miR-19b;
 hsa-miR-30a;
 hsa-miR-151-5p;
 hsa-miR-92a;
 hsa-miR-25;
 hsa-miR-15b;
 hsa-miR-15a;
 hsa-miR-30e*;
 hsa-miR-132*;
 and
 hsa-miR-921.

17. The biomarker of claim 13, wherein the microRNAs are underexpressed in colorectal neoplasia and are selected from:

hsa-miR-636;
 hsa-miR-876-3p;
 hsa-miR-1537;
 hsa-miR-630;
 hsa-miR-380*;
 hsa-miR-338-5p;
 hsa-miR-573;
 hsa-miR-182*;
 hsa-miR-518c*;
 hsa-miR-187*;
 hsa-miR-1233;
 hsa-miR-449b;
 hsa-miR-1204;
 hsa-miR-518d-3p;
 hsa-miR-1290;
 hsa-miR-144:9.1;
 hsa-miR-105;
 hsa-miR-298;
 hsa-miR-491-5p;
 hsa-miR-576-3p;
 hsa-miR-590-3p;
 hsa-miR-1257;
 hsa-miR-1225-3p;
 hsa-miR-127-3p;
 hsa-miR-936;
 hsa-miR-379;
 hsa-miR-664*;
 hsa-miR-548j;
 hsa-miR-130b*;
 and
 hsa-miR-515-3p.

18. The biomarker of claim 13, wherein the microRNAs are overexpressed in colorectal neoplasia and are selected from:

hsa-miR-302b;
 hsa-miR-125a-5p;